Speaker Profile
Thomas Hoeg Jensen

Thomas Hoeg Jensen PhD

Pharmacy and Medicine
Bagsværd, Copenhagen (Hovedstaden), Denmark

Connect with the speaker?

Thomas Hoeg-Jensen has 23 years of experience in design and preparation of diabetes-related peptide and protein drug candidates, and Thomas is co-inventor of insulin degludec (Tresiba) and the basal-bolus co-formulation with insulin aspart (Ryzodeg), both of which are marketed by Novo Nordisk. Thomas is adjunct professor at University of Copenhagen, and apart from drug discovery his research has included novel protein conjugation methods, glucose binding molecules and chemoinformatics systems for chemically modified proteins.
EVENTS & ACTIVITIES (Speaking, Spoken, and Authored)